Jose Lutzky
University of Miami · 219 works · 25,961 citations · h-index 47
Top works
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study
- Phase III Comparison of Vitespen, an Autologous Tumor-Derived Heat Shock Protein gp96 Peptide Complex Vaccine, With Physician's Choice of Treatment for Stage IV Melanoma: The C-100-21 Study Group
- Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma
- Cytotoxic T-Lymphocyte-Associated Antigen 4 Antibody-Induced Colitis and Its Management with Infliximab
- Dose effect of ipilimumab in patients with advanced melanoma: Results from a phase II, randomized, dose-ranging study
- Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial
- Clinical activity and biomarkers of MEDI4736, an anti-PD-L1 antibody, in patients with NSCLC.
- Preliminary data from a multi-arm expansion study of MEDI4736, an anti-PD-L1 antibody.
- Effect of Selumetinib vs Chemotherapy on Progression-Free Survival in Uveal Melanoma
- Intracellular distribution and pharmacokinetics of daunorubicin in anthracycline-sensitive and -resistant HL-60 cells.
- Safety and clinical activity of MEDI4736, an anti-programmed cell death-ligand 1 (PD-L1) antibody, in patients with non-small cell lung cancer (NSCLC).
- Lifileucel, a Tumor-Infiltrating Lymphocyte Therapy, in Metastatic Melanoma
- Dose‐dependent, complete response to imatinib of a metastatic mucosal melanoma with a K642E KIT mutation
- Association between immune-related adverse events (irAEs) and disease control or overall survival in patients (pts) with advanced melanoma treated with 10 mg/kg ipilimumab in three phase II clinical trials
- A phase 1 study of MEDI4736, an anti–PD-L1 antibody, in patients with advanced solid tumors.
- A phase II study of imatinib mesylate (IM) for patients with advanced melanoma harboring somatic alterations of KIT
- First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma
- The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma
- Role of glutathione and dependent enzymes in anthracycline-resistant HL60/AR cells.